Supernus Pharmaceuticals (SUPN) Receivables - Other (2012 - 2026)

Supernus Pharmaceuticals (SUPN) has 6 years of Receivables - Other data on file, last reported at $1.9 million in Q1 2026.

• On a quarterly basis, Receivables - Other changed N/A year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $1.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.8 million, down 55.0% from the prior year.
• Receivables - Other for Q1 2026 stood at $1.9 million, up from $1.8 million in the prior quarter.
• Over the last five years, Receivables - Other for SUPN reached as high as $6.3 million in Q3 2025 and fell as low as $1.8 million in Q4 2025.
• Historically, Receivables - Other has averaged $3.9 million across 3 years, with a median of $4.0 million in 2024.
• On a YoY basis, Receivables - Other climbed as much as 55.0% in 2025 and fell as far as 55.0% in 2025.
• Year by year, Receivables - Other stood at $4.0 million in 2024, then sank by 55.0% to $1.8 million in 2025, then advanced by 5.56% to $1.9 million in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $1.9 million in Q1 2026, $1.8 million in Q4 2025, and $6.3 million in Q3 2025.